<DOC>
	<DOC>NCT00356408</DOC>
	<brief_summary>This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059 (COSPAR I, NCT00349752).</brief_summary>
	<brief_title>Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients previously enrolled in C87059 (COSPAR I, NCT00349752) Subject withdrawn or discontinued from C87059 (COSPAR I, NCT00349752) study under specific conditions Subject who received treatment other than study medication and other than medications permitted in C87059 (COSPAR I, NCT00349752) Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>CDP870</keyword>
	<keyword>certolizumab pegol</keyword>
	<keyword>Crohn's Disease</keyword>
</DOC>